AU2002319180A1 - Pyruvate-kinase as a novel target molecule - Google Patents
Pyruvate-kinase as a novel target moleculeInfo
- Publication number
- AU2002319180A1 AU2002319180A1 AU2002319180A AU2002319180A AU2002319180A1 AU 2002319180 A1 AU2002319180 A1 AU 2002319180A1 AU 2002319180 A AU2002319180 A AU 2002319180A AU 2002319180 A AU2002319180 A AU 2002319180A AU 2002319180 A1 AU2002319180 A1 AU 2002319180A1
- Authority
- AU
- Australia
- Prior art keywords
- kinase
- pyruvate
- apoptosis
- cells
- activity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108020005115 Pyruvate Kinase Proteins 0.000 title claims description 99
- 102000013009 Pyruvate Kinase Human genes 0.000 title claims description 99
- MJKYGUXBFYGLLM-UHFFFAOYSA-N cyclohexanamine;2-phosphonooxyprop-2-enoic acid Chemical compound NC1CCCCC1.NC1CCCCC1.NC1CCCCC1.OC(=O)C(=C)OP(O)(O)=O MJKYGUXBFYGLLM-UHFFFAOYSA-N 0.000 title claims description 92
- 230000000694 effects Effects 0.000 claims description 44
- 230000006907 apoptotic process Effects 0.000 claims description 26
- 150000007523 nucleic acids Chemical class 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 14
- 239000000126 substance Substances 0.000 claims description 14
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 108010029485 Protein Isoforms Proteins 0.000 claims description 11
- 102000001708 Protein Isoforms Human genes 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 108010044467 Isoenzymes Proteins 0.000 claims description 9
- 206010028980 Neoplasm Diseases 0.000 claims description 8
- 230000005945 translocation Effects 0.000 claims description 7
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000003745 diagnosis Methods 0.000 claims description 5
- 208000027866 inflammatory disease Diseases 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 201000010099 disease Diseases 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 238000012216 screening Methods 0.000 claims description 4
- 239000002671 adjuvant Substances 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 230000003463 hyperproliferative effect Effects 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 230000006654 negative regulation of apoptotic process Effects 0.000 claims description 2
- 230000006659 positive regulation of apoptotic process Effects 0.000 claims description 2
- 230000004054 inflammatory process Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 61
- 210000004940 nucleus Anatomy 0.000 description 21
- 230000005937 nuclear translocation Effects 0.000 description 15
- 230000001640 apoptogenic effect Effects 0.000 description 14
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 12
- 230000014509 gene expression Effects 0.000 description 11
- 239000013598 vector Substances 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 230000004807 localization Effects 0.000 description 8
- 239000012634 fragment Substances 0.000 description 7
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 7
- 108090000623 proteins and genes Proteins 0.000 description 7
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 7
- 229940075620 somatostatin analogue Drugs 0.000 description 7
- 238000001262 western blot Methods 0.000 description 7
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 6
- 101001091538 Homo sapiens Pyruvate kinase PKM Proteins 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 108091000080 Phosphotransferase Proteins 0.000 description 6
- 102100034911 Pyruvate kinase PKM Human genes 0.000 description 6
- 150000001413 amino acids Chemical group 0.000 description 6
- 239000013592 cell lysate Substances 0.000 description 6
- 230000001086 cytosolic effect Effects 0.000 description 6
- 229960002163 hydrogen peroxide Drugs 0.000 description 6
- 102000020233 phosphotransferase Human genes 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 108091028043 Nucleic acid sequence Proteins 0.000 description 5
- 102000004243 Tubulin Human genes 0.000 description 5
- 108090000704 Tubulin Proteins 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 230000015556 catabolic process Effects 0.000 description 4
- 238000006731 degradation reaction Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 230000002414 glycolytic effect Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- XPYBSIWDXQFNMH-UHFFFAOYSA-N D-fructose 1,6-bisphosphate Natural products OP(=O)(O)OCC(O)C(O)C(O)C(=O)COP(O)(O)=O XPYBSIWDXQFNMH-UHFFFAOYSA-N 0.000 description 3
- 238000000134 MTT assay Methods 0.000 description 3
- 231100000002 MTT assay Toxicity 0.000 description 3
- RNBGYGVWRKECFJ-ZXXMMSQZSA-N alpha-D-fructofuranose 1,6-bisphosphate Chemical compound O[C@H]1[C@H](O)[C@](O)(COP(O)(O)=O)O[C@@H]1COP(O)(O)=O RNBGYGVWRKECFJ-ZXXMMSQZSA-N 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000003197 catalytic effect Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 239000013613 expression plasmid Substances 0.000 description 3
- RNBGYGVWRKECFJ-UHFFFAOYSA-N fructose-1,6-phosphate Natural products OC1C(O)C(O)(COP(O)(O)=O)OC1COP(O)(O)=O RNBGYGVWRKECFJ-UHFFFAOYSA-N 0.000 description 3
- 108020001507 fusion proteins Proteins 0.000 description 3
- 102000037865 fusion proteins Human genes 0.000 description 3
- 239000011544 gradient gel Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 238000012758 nuclear staining Methods 0.000 description 3
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 229960000553 somatostatin Drugs 0.000 description 3
- 230000004936 stimulating effect Effects 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102000011727 Caspases Human genes 0.000 description 2
- 108010076667 Caspases Proteins 0.000 description 2
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 108010056088 Somatostatin Proteins 0.000 description 2
- 102000005157 Somatostatin Human genes 0.000 description 2
- -1 TT-232 somatostatin analogue Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000012744 immunostaining Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000007590 Calpain Human genes 0.000 description 1
- 108010032088 Calpain Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 230000007018 DNA scission Effects 0.000 description 1
- 101001007826 Geobacillus stearothermophilus Pyruvate kinase Proteins 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 238000010867 Hoechst staining Methods 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 241001072332 Monia Species 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000375392 Tana Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- MGSKVZWGBWPBTF-UHFFFAOYSA-N aebsf Chemical compound NCCC1=CC=C(S(F)(=O)=O)C=C1 MGSKVZWGBWPBTF-UHFFFAOYSA-N 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000000074 antisense oligonucleotide Substances 0.000 description 1
- 238000012230 antisense oligonucleotides Methods 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 238000000423 cell based assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000004590 computer program Methods 0.000 description 1
- 238000004624 confocal microscopy Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012864 cross contamination Methods 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 230000030609 dephosphorylation Effects 0.000 description 1
- 238000006209 dephosphorylation reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 230000034659 glycolysis Effects 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000012188 high-throughput screening assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 201000010893 malignant breast melanoma Diseases 0.000 description 1
- MCPLVIGCWWTHFH-UHFFFAOYSA-L methyl blue Chemical compound [Na+].[Na+].C1=CC(S(=O)(=O)[O-])=CC=C1NC1=CC=C(C(=C2C=CC(C=C2)=[NH+]C=2C=CC(=CC=2)S([O-])(=O)=O)C=2C=CC(NC=3C=CC(=CC=3)S([O-])(=O)=O)=CC=2)C=C1 MCPLVIGCWWTHFH-UHFFFAOYSA-L 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 238000000302 molecular modelling Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000001537 neural effect Effects 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 238000012342 propidium iodide staining Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 230000006337 proteolytic cleavage Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000007423 screening assay Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
Description
Pyruvate-kinase as a novel target molecule
Description
The present invention relates to the use of a pyruvate-kinase or a nucleic acid coding therefor as a target for the modulation of apoptotic processes, particularly as a target molecule for the diagnosis, prevention or treatment of apoptosis-associated disorders, such as tumours.
Pyruvate-kinase (ATP:pyruvate 2-O-phosphotransferase, PK), is a rate- controlling glycolytic enzyme and catalyses the formation of pyruvate and ATP from phosphoenolpyruvate and ADP. In mammals, PK exists as four isoenzymes named as M1 -, M2-, L- and R-types the expression of which differ from one cell type to another (Tana a et al. 1 967, Ibsen et al. 1974, Nowak et al. 1 981 ). The M2-type considered to be the prototype, is predominant in the foetus, in neuplasias and in undifferentiated or proliferating tissues, but also widely distributed in adult tissues (Mallati et al. 1 992, Guminska et al. 1988). This form is progressively replaced by the M 1 -type in skeletal muscle, heart and brain during differentiation. Carcinogenesis apparently reverses this process. The M1 - and M2-type are produced from the same gene by alternative splicing. The difference between these two isoforms is in one exon encoding 51 amino acid residues, in which 21 residues are different. The enzymologicai property of the M1 -type isoenzyme is very different from the other three forms since it is the only one that is allosterically not regulated. The M 1 -type shows hyperbolic kinetics and is not activated by fructose-1 ,6-bisphosphate (FBP) in contrast, M2-type shows kinetic curve and is activated by FBP (Saheki et al. 1 982).
The glycolytic enzyme glyceraldehyde-3-phosphate dehydrogenase exhibits functions unrelated to its glycolytic activity and plays a role in diverse
cellular processes. For example GAPDH has been shown to translocate to the nucleus and induce apoptosis, to bind specific t-RNAs and possibly be involved in activation of transcription. There has, however, been no suggestion in the published literature that pyruvate-kinase is associated with apoptotic processes.
Thus, it was surprising that the anti-proliferative somatostatin analogue TT- 232 (Keri et al., 1 993a, Keri et al. 1 993b and Keri et al. 1 996) binds to pyruvate-kinase, particularly pyruvate-kinase isoenzyme M2. The binding of TT-232 to pyruvate-kinase leads to a nuclear translocation and an induction of apoptosis. This result demonstrates that pyruvate-kinase is involved in apoptotic processes and represents a target molecule for the development of novel drugs, particularly of drugs against cancer and inflammatory diseases.
In a first aspect the present invention relates to the use of a pyruvate- kinase or a nucleic acid encoding a pyruvate-kinase as a target for the modulation of apoptosis.
A further aspect of the present invention relates to the manufacture of an agent which modulates the activity of pyruvate-kinase for the diagnosis, prevention or treatment of an apoptosis-associated disorder.
A third aspect of the present invention relates to a method of identifying novel modulators of apoptosis comprising screening for substances capable of modulating pyruvate-kinase activity.
The term "pyruvate-kinase" as used in the present application encompasses pyruvate-kinases selected from isoenzymes M 1 , M2, L and R, as well as other isoenzymes. Particularly, the pyruvate-kinase is isoenzyme M1 (Swiss-Prot. number P1461 8) or isoenzyme M2 (Swiss-Prot. number 1 4786) . The DNA sequence encoding pyruvate kinase isoforms M 1
and M2 is disclosed in Genbank Accession number X56494. Pyruvate- kinases are obtainable from human or non-human animal sources, particularly from mammalian sources, such as man, mouse, rat, hamster, monkey, pig, etc. Especially preferred is the human M2-pyruvate-kinase comprising:
a) the amino acid sequence as shown in Swiss-Prot. number P14786 or
b) an amino acid sequence having an identity of at least 80%, particularly of at least 90% and more particularly of at least 95% thereto, wherein the amino acid sequence identity may be determined by a suitable computer-program, such as GCG or BLAST.
Furthermore, the term "pyruvate-kinase" encompasses recombinant derivatives or variants thereof, as well as fragments thereof having biological activity. These derivatives, variants and fragments thereof may be obtained as expression products from allelic variant genes or from recombinantly altered ones, e.g. modified or truncated genes and/or as products of protolytic cleavage. The term "biological activity" or "activity" in context with pyruvate-kinase preferably comprises the ability to modulate apoptosis, particularly the binding to the somatostatin analogue TT-223 and/or the translocation into the nucleus. Particularly important residues for pyruvate-kinase activity are the amino acid residues 334-420 containing a nuclear localisation signal.
A particularly preferred pyruvate-kinase variant is a nuclear pyruvate-kinase isoform which differs from cytosolic pyruvate-kinase in that it exhibits a higher electrophoretic mobility. The nuclear isoform may be obtained from the cytosolic isoform by nuclear translocation and processing.
The pyruvate-kinase protein is encoded by a nucleic acid which may be a DNA or an RNA. Preferably, the nucleic acid comprises
(a) the nucleic acid sequence as shown in Genbank Accession number X56494 or complementary thereto
(b) a nucleic acid sequence corresponding to the sequence corresponding to (a) within the scope of degeneracy of the genetic code or
(c) a nucleic acid sequence hybridizing under stringent conditions with a sequence of (a) and/or (b).
The term "hybridization under stringent conditions" according to the present application is used as described in Sambrook et al., Molecular
Cloning, A Laboratory Manual, Cold Spring Harbor, Laboratory Press
( 1 989), 1 .1 01 -1 .104. Consequently, hybridization under stringent conditions occurs when a positive hybridization signal is still detected after washing for 1 h with 1 x SSC and 0.1 % SDS at 55°C, preferably at 62°C and most preferably 68°C, in particular for 1 h in 0.2 x SSC and 0.1 % SDS at 55°C, preferably at 62°C and most preferably at 68°C. A nucleotide sequence hybridizing under such washing conditions with a sequence as shown in the sequence listing or a complementary nucleotide sequence or a sequence within the scope of degeneracy of the genetic code is encompassed by the present invention.
The nucleic acid molecules of the invention may be recombinant nucleic acid molecules generated by recombinant methods, e.g. by known amplification procedures such as PCR. On the other hand, the nucleic acid molecules can also be chemically synthesized nucleic acids. Preferably, the nucleic acid molecules are present in a vector, which may be any prokaryotic or eukaryotic vector, on which the nucleic acid sequence is
present preferably under control of a suitable expression signal, e.g. promoter, operator, enhancer etc. Examples of prokaryotic vectors are chromosomal vectors such as bacteriophages and extrachromosomal vectors such as plasmids, wherein circular plasmid vectors are preferred. Examples of eukaryotic vectors are yeast vectors or vectors suitable for higher cells, e.g. insect cells or mammalian cells, plasmids or viruses.
The pyruvate-kinase is capable of binding somatostatin analogue TT-232 and mediating its effect, particularly its effect to stimulate apoptotic processes. Thus, a stimulation of apoptosis may be obtained by increasing the amount and/or activity of pyruvate-kinase, particularly the nuclear translocation activity. In contrast thereto, an inhibition of apoptosis may be obtained by reducing the activity of pyruvate-kinase, particularly the nuclear translocation activity.
A preferred embodiment of the present invention comprises increasing the activity of a pyruvate-kinase in a target cell or a target organism, particularly a mammalian cell or a mammal including a human being. This increase in activity may be accomplished by administering a substance capable of binding to pyruvate-kinase and stimulating its apoptotic activity, particularly its nuclear translocation activity. This activator may be a low molecular weight substance or an anti-pyruvate-kinase antibody, e.g. a polyclonal antiserum, a monoclonal antibody, antibody fragments, recombinant antibodies etc. In a further preferred embodiment the invention comprises increasing the expression of pyruvate-kinase in a target cell or a target organism. This increase may be accomplished by administration of pyruvate-kinase, fragments or analogues thereof, or by gene-therapeutic administration of pyruvate-kinase encoding nucleic acids.
A further preferred embodiment of the present invention comprises reducing the activity of a pyruvate-kinase in a target cell or a target organism. This reduction in activity may be accomplished by administering
a substance capable of inhibiting the apoptotic activity of pyruvate-kinase. This inhibitor may be a low molecular weight substance or an anti- pyruvate-kinase antibody. Further, the expression of pyruvate-kinase in a target cell or target organism may be reduced by administration of anti- sense oligonucleotides, ribozymes or other expression-inhibiting nucleic acids.
Due to its activity, pyruvate-kinase is a suitable target for the manufacture of agents for the diagnosis, prevention or treatment of an apoptosis- associated disorder, particularly a hyperproliferative disease which may be selected from tumours, e.g. colon cancer, breast cancer or melanomas and inflammatory diseases, e.g. neuronal inflammatory diseases, such as neuroarthritis, or a degenerative disease.
The administration of an pyruvate-kinase-modulating agent is preferably in the form of a pharmaceutical composition which additionally comprises suitable pharmaceutically acceptable carriers, diluents or adjuvants. The composition may be an injectable solution, a suspension, a cream, an ointment, a tablet, etc. The composition may be suitable for diagnostic, preventive or therapeutic applications, particularly in the field of cancer. The dosage and mode of administration route depends on the type and the variety of the disorder to be treated and may be determined readily by a skilled practitioner.
For example, the administration of antibodies may be carried out according to known protocols, e.g. as described by Baselga (2000). The administration in form of nucleic acids may also be carried out according to known protocols, such as described by Monia (2000).
The administration of pyruvate-kinase modulators may be combined with the administration of other active agents, particularly anti-tumour agents,
e.g. cytotoxic substances and MAP-kinase inhibitors, such as PD98059 and UO1 26.
Still a further embodiment of the present invention is a method of identifying novel modulators of apoptosis comprising screening for substances capable of modulating pyruvate-kinase activity. Particularly, the invention relates to a method of identifying substances capable of binding to pyruvate-kinase and stimulating translocation to the nucleus.
The screening method may be a high throughput screening assay, wherein a plurality of substances is tested in parallel. The screening assay may be a cellular assay or a molecular assay, wherein an interaction of a substance to be tested with pyruvate-kinase activity is determined. Pyruvate-kinase may be provided in a cellular system, preferably in a cellular system overexpressing pyruvate-kinase, e.g. a cell culture or an animal model. On the other hand, non-cellular systems may be used, e.g. pyruvate-kinase containing cell fractions or substantially isolated and purified pyruvate- kinase. Any active substance identified by this method, e.g. any substance capable of modulating, particularly stimulating nuclear translocation of pyruvate-kinase may be used as a pharmaceutical agent or as a lead structure which is further modified to improve pharmaceutical properties. Thus, the invention further comprises formulating a pyruvate-kinase modulator, as identified by the method as described above or a substance obtained therefrom, e.g. by chemical derivatization or by molecular modelling, as a pharmaceutical composition together with pharmaceutically acceptable carriers, diluents or adjuvants.
The present invention is explained in more detail in the following Figures and Examples:
Figure 1 . Schematic representation of the generated pyruvate-kinase mutants.
Figure 2. Effect of different pyruvate-kinase deletion mutants on TT-232 induced cell death.
Figure 3. Localisation of pyruvate-kinase. NIH3T3 cells were untreated (A) or treated with 50 μU TT-232 for 4 hours (B). Cells were fixed with methanol, blocked with PBS + 3% BSA and subjected to immuno-staining with polyclonal PK-M2 specific primary and FITC labelled secondary antibody (green). Nuclei were visualized with propidium-iodide staining (red, insert picture).
Figure 4. Nuclear translocation of the pyruvate-kinase upon different apoptotic stimuli. Cos-7 cells were transiently transfected with pEGFP-PK- M2 eukaryotic expression plasmid (producing wild type pyruvate-kinase N- terminally fused to GFP)
Figure 5. Nuclear translocation of the pyruvate-kinase deletion mutants upon apoptotic stimuli. Cos-7 cells were transiently transfected with pEGFP-PK-M2 eukaryotic expression plasmid (producing different deletion mutants of the pyruvate-kinase N-terminally fused to GFP) and 48 hours after transfection cells were untreated (A-L) or treated with 50 μM TT-232 for 4 hours (D'-L'). (Ex: 485 nm = GFP, Ex: 390 = propidium-iodide)
Fig. 6. In vitro binding of somatostatin and TT-232 to rabbit muscle pyruvate-kinase.
Fig. 7. Effect of overexpression of pyruvate-kinase on sensitivity towards TT-232. (A) Western-blot of total cell lysates from 293HEK with or without overexpressing HA-tagged wild type PK-M2. (B) stably transfected cells were treated with increasing concentration of TT-232 for 24 hours and the amount of living cells was measured by MTT assay. (n = 32, *: p < 0.005, * *: p < 0.001 determined by student's T-test)
Fig. 8. Subcellular localisation of endogenous PK-M2 upon peroxide or UV stimulation. Cos-7 cells were untreated, treated with 50 μM TT-232 (A), 1 00 /M hydrogen-peroxide (B), or 1 20 mJ/cm2 UV (C) and incubated for different times as indicated. Cells were separated into cytosolic (c) or nuclear (n) fractions loaded in triplicate and blotted with PK-M2 (uppest panels), Erk-2 (middle panels) or Histone H 1 (lowest panels).
Fig. 9. Effect of nuclear targeted PK-M2 on cell growth. (A and C) Cos-7 cells were transfected for 5 hours with empty vectors, pEGFP-PK-M2 (PKM2) or with pEYFP-PKM2-NLS (PKM2-NLS) (A) or pEGFP-PK-M 1 (PKM2) or with pEYFP-PKM1 -NLS (D). Cells were trypsinized, plated into 96 well plates, incubated for 24, 48, 72 hours in FCS containing medium, and cell density was measured with MTT assay. Cells were let to adhere for 1 0 hours, were measured and this was considered as zero time-point (n = 1 2 of three independent experiments). (B and D) A portion of the transfected cells was incubated for 48 hours, separated by 6-1 5% SDS- gradient gel electrophoresis and analysed in Western-blot with GFP antibody (upper panel). Reprobing the filter with tubulin antibody (lower panel) showed equal loading.
Fig. 10. Effect of nuclear targeted PK-M2 on apoptosis. Cos-7 cells were transfected wiuvpEGFP (A, A'), pEYFP-NLS (B, B'), pEGFP-PKM2 (C, C) or pEYFP-PKM2-NLS (D, D'), pEGFP-PKM 1 (E, E') or pEYFP-PKM 1 -NLS (F, F') incubated for 48 hours in FCS containing media. Cells were fixed, nuclei were stained with Hoechst and analysed under fluorescent microscope for GFP (A-F) and for nuclear staining (A'-F'). Highly fluorescent, condensed, fragmented nuclei were considered as being apoptotic (arrows).
Fig. 1 1 . Detection of DNA degradation. (A and B) Cos-7 cells were transfected with different constructs, incubated for 48 hours in FCS containing media, samples were divided in two parts, and DNA was extracted and analysed on 0,6 % agarose gel. (C and D) second part of the
sample was analysed for protein expression. Total cell lysates were loaded on 6-1 5% gradient gel and analysed in Western-blot with GFP antibody (upper panel). Reprobing the filter with tubulin antibody (lower panel) showed equal loading.
Fig. 12. Expression of kinase deficient pyruvate-kinase in Cos-7 cells. Total cell lysates were loaded on 6-1 5% gradient gel and analysed in Western- blot with GFP antibody (upper panel, GFP is indicated by arrowheads and GFP-pyruvate kinase M2 fusion proteins by arrows). Reprobing the filter with tubulin antibody (lower panel) showed equal loading.
Fig. 13. Pyruvate-kinase activity of Cos-7 cells overexpressing wild type (PKM2wt) or kinase deficient pyruvate-kinase M2 (PKM2KM) Total cell lysates were assayed for pyruvate-kinase activity by LDH coupled assay. (n = 6) .
Fig. 14. Effect of nuclear targeted kinase deficient PK-M2 on apoptosis. Cos-7 cells were transfected with pEYFP-NLS (GFP-NLS), pEYFP-PKM2wt- NLS (GFP-NLS PKM2wt) or pEYFP-PKM2 K/M-NLS (GFP-NLS PKM2 K/M) incubated for 48 hours in FCS containing media. Cells were fixed, nuclei were stained with Hoechst and analysed under fluorescent microscope for GFP (upper part)-and for nuclear staining (lower part). Highly fluorescent, condensed, fragmented nuclei were considered as being apoptotic (arrows) .
EXAMPLES
The apoptotic effect of a new tumour selective somatostatin analogue was studied; TT-232 and it was found that the compound binds to pyruvate- kinase M2. Pyruvate-kinase M2 isoform was cloned from A431 epidermoid carcinoma cell line derived RNA with PCR. Several deletion mutants of the
pyruvate-kinase isoform M2 were generated in the eukaryotic expression vector pCDNA3.1 (Invitrogen) as shown in Figure 1 .
The effect of the mutants on the induction of apoptosis by TT-232 was investigated in Cos-7 cells transiently overexpressing these mutants. The cells were transfected at 70% confluency with 1//g DNA using the Lipofectamine method. Apoptosis was induced 48 hours after transfection with 25 μM TT-232 and cells were counted 24 hours later. In order to discriminate between living or dying cells methyl-blue exclusion was used (Figure 2).
The overexpression of the N-terminal 100 amino acid of the pyruvate- kinase molecule was sufficient to block the effect of TT-232 somatostatin analogue. This result suggests that pyruvate-kinase, similarly to GAPDH, plays a role in apoptosis. However, since the activity of pyruvate-kinase was not affected by treatment with TT-232 this apoptotic effect is independent of the catalytic activity of the enzyme.
Previously the binding of PK to tubulin was reported (Ovadi et al. 1 999) and TT-232 was found to inhibit this interaction. Therefore, the localisation of pyruvate-kinase was studied in detail. NIH3T3 cells were untreated (Figure 3A) or treated with 50 μM TT-232 for 4 hours (Figure 3B), fixed with methanol and subjected to immuno-staining with polyclonal PK-M2 isoform specific and FITC labelled secondary antibody. The nucleus was visualized with propidium-iodide and staining was detected by laser confocal microscopy.
Figure 3 demonstrates that pyruvate-kinase translocates to the nucleus during treatment with the somatostatin analogue TT-232. In order to see whether this effect is a general process during apoptosis, the nuclear translocation was investigated after hydrogen peroxide and UV treatment. Cos-7 cells were transiently transfected with pEGFP-PK-M2 eukaryotic
expression plasmid and 48 hours after transfection cells were treated with 1 mM hydrogen peroxide for 4 hours. Cells were treated with 60J/cm2 UV radiation and incubated for different times. Cells were fixed with 1 % glutaraldehyde and analysed with fluorescent microscope and InoVision confocal imaging software. Figure 4 shows that the nuclear translocation of the pyruvate-kinase occurs upon treatment with peroxide-peroxide and UV confirming that the translocation of pyruvate-kinase is a general phenomenon.
Finally, we studied the location of the nuclear localisation signal. Therefore several truncated fragments of the pyruvate-kinase were fused to GFP and the localisation of these fragments was studied upon treatment with the TT-232 somatostatin analogue. The transiently transfected Cos-7 cells were untreated or treated with 50 μM TT-232 for 4 hours. Cells were fixed with 1 % glutaraldehyde and the localisation of GFP was detected and analysed with fluorescent microscope and InoVision confocal imaging software. Nuclei were stained with propidium-iodine (Figure 5).
The nuclear translocation was detectable with wild type and ΔC mutant (amino acids 1 -420) but not with PK1 -334 truncated mutant. Therefore, the pyruvate-kinase protein has a nuclear localisation signal between amino acids 334-420. :
We previously isolated pyruvate-kinase M2 as the receptor for the anticancer drug TT-232. To confirm the interaction between pyruvate- kinase M and somatostatin or TT-232 we performed an in vitro binding assay with isolated rabbit muscle pyruvate-kinase and 125l-somatostatin (SS-1 4). The binding constant (given as IC50 values) for SS-14 or TT-232 was measured by competition between radio-labelled SS-14 and "cold" peptides (Figure 6) and the radioactivity was measured with Phospholmager following gel-electrophoresis of crosslinked proteins.
To investigate the biological role of PK-M2 in the anticancer effect of TT- 232 we generated stable 293HEK cells overexpressing HA-tagged wild type PK-M2 and we measured the sensitivity of these cells to TT-232 concentrations. As shown in Figure 7 increasing the amount of pyruvate- kinase protein in cells results increased sensitivity to TT-232, suggesting those pyruvate-kinase plays an important role in the effect of the drug.
In untreated cells, PK-M2 was cytoplasmic. TT-232, hydrogen peroxide and UV induced the nuclear translocation of PK-M2 preceding the appearance of the apoptotic morphology. This result supported our previous data that, like GAPDH, pyruvate-kinase translocates into the nucleus upon apoptotic stimuli. In order investigate further Cos-7 cells were treated, separated into cytosolic and nuclear fractions by NP-40 lysis and analysed with polyclonal PKM2 specific antibody (Weernink et al., 1 988) for endogenous PK-M2 by Western-blots. To rule out cross contamination, samples were loaded in triplicate and blotted with PK-M2, Erk-2 or Histone H 1 antibodies. As shown in Figure 8, TT-232, hydrogen peroxide and UV treatment induced the translocation of the endogenous PK-M2 into the nucleus with similar kinetics.
However, the enzyme present in the nucleus showed increased electrophoretic mobility, which is probably due to proteolytic cleavage or to dephosphorylation. To test the role of proteases we pre-treated Cos-7 cells with serine-protease (AEBSF, TPCK), caspase (zDEVD) or calpain (ALLN) inhibitor, but were not able to revert this effect. This suggests that none of these proteases are responsible for the apparent processing.
Further, we investigated the role of the M2 isoform in the nucleus. Therefore, PK-M2 and PK-M1 was subcloned into pEYFP-Nuc vector carrying the SV-40 large T antigen nuclear localisation signal fused to GFP and Cos-7 cells were transfected with the different constructs. After 5 hours cells were trypsinized and plated into 96 well and 6 well plates and
grown for different times. After 10 hours MTT was added to one of the plates, was measured and this was considered as zero time point. MTT assays demonstrated a significant cell growth inhibition in cells transfected with the nuclear-targeted NLS-PK-M2, while the growth properties of Cos-7 cells carrying GFP, GFP-NLS, PK-M 1 , NLS-PK-M 1 or PK-M2 were unaffected (Fig. 9A and C). To confirm the expression of the GFP construct, Western-blots with a GFP antibody were carried out from total cell lysates out of the 6 well plates and reprobed with tubulin antibody (Fig. 9B and D).
This result suggested that the nuclear translocation of PK-M2 inhibits cell growth and/or induces apoptosis. We analysed transfected Cos-7 cells stained with Hoechst dye by fluorescent microscopy. Highly fluorescent, condensed or fragmented nuclei that showed patches of compact chromatin were considered as being apoptotic. Figure 10 shows that cells expressing the fusion protein GFP-PKM2, GFP-PKM 1 or GFP-NLS-PKM 1 showed normal nuclear staining (Fig. 4 C, E, F, C, E' and F ') similar to cells carrying GFP or GFP-NLS (Fig. 10A-B'). At the same time, GFP-PK- M2-NLS was found in the nucleus and cells expressing the protein showed apoptotic morphology (Fig. 10D and D').
This result supports that pyruvate-kinase translocation upon apoptotic stimuli is important for the commitment to cell death. This is in conjunction with previous results demonstrating that GAPDH nuclear translocation is involved in apoptosis. In order to test the effect of PK-M2-NLS overexpression on DNA fragmentation, Cos-7 cells were transfected with different constructs, following 48 hours incubation, and DNA was extracted and analysed by agarose gel electrophoresis. Expression of nuclear-targeted PK-M2 induced DNA degradation into distinct larger fragments (3500, 7000 bp) that was different from classical DNA-laddering (Fig. 1 1 ) .
Since DNA degradation during apoptosis is a multi-step process resulting first large DNA cleavage products than finally oligonucleosomal fragments, we propose that pyruvate-kinase is involved in an early step of DNA degradation, and other factors, like activation of caspases, are necessary for the further processing. Since, overexpressed nuclear targeted PK-M2 was sufficient for cell death independently on the endogenous protein, this effect is likely not due to the inhibition of the glycolysis and the depletion of ATP from cells. This hypothesis is supported by the fact that though GAPDH is related to degenerative conditions in Huntington 's disease, the glycolytic activity of the enzyme does not appear to be altered (Kagedal et al., 2001 ). To test the requirement of the activity of pyruvate-kinase in the nucleus we generated kinase deficient PK-M2 (PKM2K/M) and transfected transiently into Cos-7 cells. First, we tested the expression and processing of the different fusion proteins on Western-blots (Fig. 1 2) .
Next, we measured the pyruvate-kinase catalytic activity from total cell lysates (Fig. 1 3). Overexpression of the wild type PK-M2 significantly increased the overall PK activity (p > 0,005), while the PK activity in kinase deficient mutant expressing cells was reduced compared to mock transfected cells (p > 0,0001 ). This suggests that PKM2 K269M mutation, which affects the ATP binding site leads to catalytic inactivation of PKM protein. This is supported by the fact that overexpression of PKM2K/M mutant also interfered with the endogenous PK activity and resulted in decreased overall PK activity.
To investigate the requirement of the activity of pyruvate-kinase in the nucleus we analysed transiently transfected Cos-7 cells for apoptosis by Hoechst staining (Fig. 14) .
Taken together pyruvate-kinase was found to be the receptor of a potent antitumour agent with strong apoptotic effect. Further results showed that pyruvate-kinase plays an important role in the apoptotic process,
furthermore the enzyme translocates into the nucleus. Nuclear translocation of PK seems to be a general phenomenon, since in oxidative stress (hydrogen-peroxide) or in UV induced apoptosis pyruvate-kinase was found in the nucleus. The nuclear pyruvate-kinase isoform differs from cytosolic pyruvate-kinase in that it exhibits a higher electrophoretic mobility.
It is concluded that like GAPDH, pyruvate-kinase is involved in the apoptotic process and could be a target molecule for the development of drugs against cancer and inflammatory diseases.
REFERENCES
Tanaka, T., Harano, Y., Sue, F. and Morimura, H. (1967) J. Biochem.
(Tokyo) 62, 71-91.
Nowak, T. and Suelter, C. (1981) Mol. Cell. Biochem.35, 65-75. Ibsen, K. and Trippet, P. (1974) Arch. Biochem. Biophys.570-580.
Mallati, A., Yucel, M., Altinors, N. and Gunduz, U. (1992) Cancer Biochem.
Biophys. 13, 33-41.
Guminska, M., Stachurska, M.B. and Ignacak, J. (1988) Biochem. Biophys.
Acta 966, 207-213. Saheki, S., Saheki, K. and Tanaka, T. (1982) Biochem. Biophys. Acta 704,
484-493.
Keri, Gy., et al. (1993a) Biochem. Biophys. Res. Comm. 191, 681-687.
Keri, Gy., et al. (1993b) Peptide Research 6, 281-288.
Keri, Gy., et al. (1996), Proc. Natl. Acad. Sci. U.S.A.93, 12513-12518. Baselga (2000), Semin. Oncol.27, 27-32.
Monia (2000), Cancer Invest.18, 635-650.
Vertessy, B.G., Bankfalvi, D., Kovacs, J., Low, P., Lehotzky, A. and Ovadi,
J. (1999) Biochem. Biophys. Res. Comm.254, 430-435.
Weernink, P.A.O., Rijksen, G. and Staal, G.E.J. (1988) FEBS Letters 236, 391-395.
Kagedal, K., Johansson, U. and Ollinger, K. FASEB J.2001 15, 1592-4.
Claims
1 . Use of a pyruvate-kinase or a nucleic acid encoding a pyruvate- kinase as a target for the modulation of apoptosis.
2. The use of claim 1 comprising a stimulation of apoptosis by increasing the activity of pyruvate-kinase.
3. The use of claim 1 comprising an inhibition of apoptosis by reducing the activity of pyruvate-kinase.
4. The use of any one of claims 1 -4 wherein the activity comprises a translocation to the nucleus. 5
5. The use of any one of claims 1 -4 wherein the pyruvate-kinase is selected from isoenzymes M1 , M2, L and R.
6. The use of claim 4 wherein the pyruvate-kinase is isoenzyme M2. 0
7. The use of any one of claims 1 -6 for the manufacture of an agent for the diagnosis, prevention or treatment of an apoptosis-associated disorder.
5 8. The use of claim 7, wherein the disorder is a hyperproliferative disease, e.g. selected from tumours and inflammatory diseases.
9. A method of identifying novel modulators of apoptosis comprising screening for substances capable of modulating pyruvate-kinase o activity.
10. The method of claim 9 wherein the activity comprises a translocation to the nucleus.
1 1 . The method of claim 9 or 10 further comprising formulating a pyruvate-kinase modulator or a substance obtained therefrom as a pharmaceutical composition together with pharmaceutically acceptable carriers, diluents or adjuvants.
12. The method of claim 1 1 wherein the pharmaceutical composition is suitable for the diagnosis, prevention or treatment of an apoptosis- associated disorder, such as a hyperproliferative disease, e.g. selected from tumours and inflammatory processes.
13. Nuclear pyruvate-kinase isoform.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP01112601.8 | 2001-05-23 | ||
| EP01112601 | 2001-05-23 | ||
| PCT/EP2002/005684 WO2002095063A1 (en) | 2001-05-23 | 2002-05-23 | Pyruvate-kinase as a novel target molecule |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002319180A1 true AU2002319180A1 (en) | 2003-05-08 |
| AU2002319180B2 AU2002319180B2 (en) | 2007-07-05 |
Family
ID=8177529
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002319180A Ceased AU2002319180B2 (en) | 2001-05-23 | 2002-05-23 | Pyruvate-kinase as a novel target molecule |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20040152648A1 (en) |
| EP (2) | EP1990422A1 (en) |
| AT (1) | ATE404691T1 (en) |
| AU (1) | AU2002319180B2 (en) |
| CA (1) | CA2448165A1 (en) |
| DE (1) | DE60228233D1 (en) |
| DK (1) | DK1390525T3 (en) |
| ES (1) | ES2312595T3 (en) |
| PT (1) | PT1390525E (en) |
| WO (1) | WO2002095063A1 (en) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003266272A1 (en) * | 2002-08-12 | 2004-03-03 | Amynon Bio Tech Gmbh | Peptide modulators of tumour specific pyruvate kinase subtype m2 (m2-pk) |
| JP2006517788A (en) * | 2002-12-20 | 2006-08-03 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476, 62113, 64316, 12264, 32362, 58198, 2887, 3205, 8557, 9600, 9693, 44867, 53058, 55556, 57658, 2208, 10252, 10302, 1421 , Methods and compositions for treating cancer using the 33877,10317,10485,25964,14815,1363,1397,14827,21708,3801,64698,2179 or 13249 |
| DE10356218A1 (en) * | 2003-12-03 | 2005-06-30 | Bayer Cropscience Ag | A method for identifying fungicidally active compounds based on pyruvate kinases from fungi |
| WO2006055880A2 (en) * | 2004-11-16 | 2006-05-26 | Genzyme Corporation | Diagnostic pkm2 methods and compositions |
| US20060166236A1 (en) * | 2004-12-15 | 2006-07-27 | Chong-Sheng Yuan | Allosteric enzyme coupled immunoassay (AECIA) |
| WO2009025781A1 (en) * | 2007-08-16 | 2009-02-26 | Beth Israel Deaconess Medical Center | Activators of pyruvate kinase m2 and methods of treating disease |
| US8841305B2 (en) * | 2008-10-09 | 2014-09-23 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Activators of the human pyruvate kinase M2 receptor |
| JP5756457B2 (en) | 2009-04-06 | 2015-07-29 | アジオス ファーマシューティカルズ， インコーポレイテッド | Pyruvate kinase M2 modulators, therapeutic compositions and related methods of use |
| WO2010129596A1 (en) | 2009-05-04 | 2010-11-11 | Agios Pharmaceuticals, Inc. | Pmk2 modulators for use in the treatment of cancer |
| ES2632954T3 (en) * | 2009-06-29 | 2017-09-18 | Agios Pharmaceuticals, Inc. | Quinoline-8-sulfonamide derivatives that have an anticancer activity |
| DK2448581T3 (en) | 2009-06-29 | 2017-03-13 | Agios Pharmaceuticals Inc | Therapeutic compositions and methods for their applications |
| EP2525790B1 (en) | 2009-10-21 | 2020-05-27 | Agios Pharmaceuticals, Inc. | Methods and compositions for cell-proliferation-related disorders |
| EP3064595B1 (en) | 2009-10-21 | 2019-02-27 | Agios Pharmaceuticals, Inc. | Methods for cell-proliferation-related disorders |
| EP2542267A4 (en) | 2010-03-05 | 2014-09-17 | Univ Columbia | RNA INHIBITORS OF RNA BINDING PROTEINS HNRNPA1, HNRNPA2 AND PTB AND USES THEREOF |
| WO2011137089A1 (en) | 2010-04-29 | 2011-11-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Activators of human pyruvate kinase |
| ES2564952T3 (en) | 2010-12-17 | 2016-03-30 | Agios Pharmaceuticals, Inc. | New derivatives of N- (4- (azetidine-1-carbonyl) phenyl) - (hetero-) arylsulfonamide as modulators of pyruvate kinase M2 (PKM2) |
| ES2569712T3 (en) | 2010-12-21 | 2016-05-12 | Agios Pharmaceuticals, Inc. | PKM2 bicyclic activators |
| TWI549947B (en) | 2010-12-29 | 2016-09-21 | 阿吉歐斯製藥公司 | Therapeutic compounds and compositions |
| PT2704721T (en) | 2011-05-03 | 2018-06-14 | Agios Pharmaceuticals Inc | Pyruvate kinase activators for use in therapy |
| RS64777B1 (en) | 2015-06-11 | 2023-11-30 | Agios Pharmaceuticals Inc | Methods of using pyruvate kinase activators |
| WO2018175474A1 (en) | 2017-03-20 | 2018-09-27 | Forma Therapeutics, Inc. | Pyrrolopyrrole compositions as pyruvate kinase (pkr) activators |
| US10675274B2 (en) | 2018-09-19 | 2020-06-09 | Forma Therapeutics, Inc. | Activating pyruvate kinase R |
| JP7450610B2 (en) | 2018-09-19 | 2024-03-15 | ノヴォ・ノルディスク・ヘルス・ケア・アーゲー | Activation of pyruvate kinase R |
| CN114650817A (en) | 2019-09-19 | 2022-06-21 | 福马治疗股份有限公司 | Activation of pyruvate kinase R |
| US12128035B2 (en) | 2021-03-19 | 2024-10-29 | Novo Nordisk Health Care Ag | Activating pyruvate kinase R |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5821254A (en) * | 1995-02-17 | 1998-10-13 | The United States Of America As Represented By The Department Of Health And Human Services | Uses of 9-cis-retinoic acids and derivatives thereof alone or in combination with antineoplastic agents in the prevention or treatment of cancer |
| AU6333598A (en) * | 1997-02-11 | 1998-08-26 | Regents Of The University Of California, The | Methods of inducing cell cycle stasis |
| US7074895B2 (en) * | 1997-08-21 | 2006-07-11 | Quark Biotech, Inc. | Sequences characteristic of hypoxia-regulated gene transcription |
| US5948628A (en) * | 1997-09-05 | 1999-09-07 | The Board Of Regents Of The University Of Oklahoma | Methods of screening for compounds which mimic galectin-1 |
| US6458538B1 (en) * | 1999-12-14 | 2002-10-01 | Ptc Therapeutics, Inc. | Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay |
-
2002
- 2002-05-23 AU AU2002319180A patent/AU2002319180B2/en not_active Ceased
- 2002-05-23 PT PT02748716T patent/PT1390525E/en unknown
- 2002-05-23 DE DE60228233T patent/DE60228233D1/en not_active Expired - Lifetime
- 2002-05-23 EP EP08014232A patent/EP1990422A1/en not_active Withdrawn
- 2002-05-23 US US10/478,679 patent/US20040152648A1/en not_active Abandoned
- 2002-05-23 AT AT02748716T patent/ATE404691T1/en not_active IP Right Cessation
- 2002-05-23 WO PCT/EP2002/005684 patent/WO2002095063A1/en active IP Right Grant
- 2002-05-23 EP EP02748716A patent/EP1390525B8/en not_active Expired - Lifetime
- 2002-05-23 DK DK02748716T patent/DK1390525T3/en active
- 2002-05-23 CA CA002448165A patent/CA2448165A1/en not_active Abandoned
- 2002-05-23 ES ES02748716T patent/ES2312595T3/en not_active Expired - Lifetime
-
2007
- 2007-06-29 US US11/771,462 patent/US20080021116A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080021116A1 (en) | Pyruvate-kinase as a novel target molecule | |
| AU2002319180A1 (en) | Pyruvate-kinase as a novel target molecule | |
| Whitesell et al. | Geldanamycin-stimulated destabilization of mutated p53 is mediated by the proteasome in vivo | |
| Boudeau et al. | Heat-shock protein 90 and Cdc37 interact with LKB1 and regulate its stability | |
| D'Orazi et al. | Homeodomain-interacting protein kinase-2 phosphorylates p53 at Ser 46 and mediates apoptosis | |
| US7459282B2 (en) | Use of c-Jun or c-Jun activating agents such as UV or c-Jun N-terminal kinases (JNKs) for treating cancer | |
| US7745109B2 (en) | Regulation of cell growth by MUC1 | |
| US7510850B2 (en) | Isolation of the mitotic spindle matrix and its methods of use | |
| Rehman et al. | Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells | |
| EP2056111A1 (en) | Methods and compositions for regulating protein-protein interactions | |
| AU2002246791A1 (en) | Regulation of cell growth by MUC1 | |
| Tian et al. | Interaction of LDL receptor‐related protein 4 (LRP4) with postsynaptic scaffold proteins via its C‐terminal PDZ domain‐binding motif, and its regulation by Ca2+/calmodulin‐dependent protein kinase II | |
| US20080171797A1 (en) | Methods of modulating mitochondrial nad-dependent deacetylase | |
| Wobst et al. | UCHL 1 regulates ubiquitination and recycling of the neural cell adhesion molecule NCAM | |
| McDermott et al. | Nm23-H1 homologs suppress tumor cell motility and anchorage independent growth | |
| AU2001265947B2 (en) | Enzymatic assays for screening anti-cancer agents | |
| US20060094101A1 (en) | Mk2 interacting proteins | |
| US20090023794A1 (en) | Use of Sumoylation Inhibitors for the Treatment of Neurodegenerative Disease | |
| US20070072210A1 (en) | Use of brca1-associated protein to treat and screen for dna damage and to identify therapeutics that promote a dna damage response | |
| EP1212078B1 (en) | Ant-1 as drug target | |
| US10254283B2 (en) | Biomarker for MELK activity and methods of using same | |
| AU2014348780B2 (en) | Biomarker for MELK activity and methods of using same | |
| Kim | Antizyme inhibitor: A novel effector of cell growth and proliferation | |
| Lavin et al. | Regina Waltes, Reinhard Kalb, 3, 9 Magtouf Gatei, 4 Amanda W. Kijas, 4 Markus Stumm, 5 Alexandra Sobeck, 3 Britta Wieland, Raymonda Varon, 6 Yaniv Lerenthal, 7 |